Replies to post #69996 on Biotech Values

[DewDiligence]

>KG received a Complete Response Letter from the FDA for on REMOXY's NDA. Additional non-clinical data will be required.<

Well, they still have Embeda. Maybe KG is banking on opioid ‘fungibility’ after all.